Clinical Trial Update: Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan [Phase 3]

View source ↗

Summary

Phase 3 open-label trial update for QTI571 (selexipag? or QTI571) provided to PAH patients who participated in an extension study in Japan; status completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• QTI571 (QTI571)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Severe Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2019-06-18